These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


116 related items for PubMed ID: 20031208

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A, Tan YV, Ceraudo E, Lacapère JJ, Murail S, Neumann JM, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
    [Abstract] [Full Text] [Related]

  • 3. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A, Tan YV, Ceraudo E, Laburthe M.
    Methods Enzymol; 2013 Jul; 520():219-37. PubMed ID: 23332702
    [Abstract] [Full Text] [Related]

  • 4. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
    Couvineau A, Laburthe M.
    Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
    Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, Robert JC, Jamin N, Neumann JM, Robberecht P, Laburthe M, Couvineau A.
    FASEB J; 2012 May; 26(5):2060-71. PubMed ID: 22291440
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E, Murail S, Tan YV, Lacapère JJ, Neumann JM, Couvineau A, Laburthe M.
    Mol Endocrinol; 2008 Jan; 22(1):147-55. PubMed ID: 17885205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Ceraudo E, Tan YV, Nicole P, Couvineau A, Laburthe M.
    J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186
    [Abstract] [Full Text] [Related]

  • 12. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
    Laburthe M, Couvineau A, Tan V.
    Peptides; 2007 Sep; 28(9):1631-9. PubMed ID: 17574305
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Apr 15; 162(8):4685-96. PubMed ID: 10202009
    [Abstract] [Full Text] [Related]

  • 19. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D, Ribeiro JA, Sebastião AM.
    Brain Res; 2005 Jul 05; 1049(1):52-60. PubMed ID: 15935995
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.